Abstract
Nucleobindin-2 is a 420 amino acid EF-hand Ca2+ binding protein that can be further processed to generate an 82 amino terminal peptide termed Nesfatin-1. To examine the function of secreted Nucleobindin-2 in adipocyte differentiation, cultured 3T3-L1 cells were incubated with either 0 or 100 nM of GST, GST-Nucleobindin-2, prior to and during the initiation of adipocyte differentiation. Nucleobindin-2 treatment decreased neutral lipid accumulation (Oil-Red O staining) and expression of several marker genes for adipocyte differentiation (PPARγ, aP2, and adipsin). When Nucleobindin- 2 was constitutively secreted into cultured medium, cAMP content and insulin stimulated CREB phosphorylation were significantly reduced. On the other hand, intracellularly overexpressed Nucleobindin-2 failed to affect cAMP content and CREB phosphorylation. Taken together, these data indicate that secreted Nucleobindin-2 is a suppressor of adipocyte differentiation through inhibition of cAMP production and insulin signal.
Keywords: Nucleobindin-2, Nesfatin-1, adipogenesis, 3T3-L1, insulin, GST
Protein & Peptide Letters
Title:Secreted Nucleobindin-2 Inhibits 3T3-L1 Adipocyte Differentiation
Volume: 19 Issue: 9
Author(s): Yuko Tagaya, Aya Osaki, Atsuko Miura, Shuichi Okada, Kihachi Ohshima, Koshi Hashimoto, Masanobu Yamada, Tetsurou Satoh, Hiroyuki Shimizu and Masatomo Mori
Affiliation:
Keywords: Nucleobindin-2, Nesfatin-1, adipogenesis, 3T3-L1, insulin, GST
Abstract: Nucleobindin-2 is a 420 amino acid EF-hand Ca2+ binding protein that can be further processed to generate an 82 amino terminal peptide termed Nesfatin-1. To examine the function of secreted Nucleobindin-2 in adipocyte differentiation, cultured 3T3-L1 cells were incubated with either 0 or 100 nM of GST, GST-Nucleobindin-2, prior to and during the initiation of adipocyte differentiation. Nucleobindin-2 treatment decreased neutral lipid accumulation (Oil-Red O staining) and expression of several marker genes for adipocyte differentiation (PPARγ, aP2, and adipsin). When Nucleobindin- 2 was constitutively secreted into cultured medium, cAMP content and insulin stimulated CREB phosphorylation were significantly reduced. On the other hand, intracellularly overexpressed Nucleobindin-2 failed to affect cAMP content and CREB phosphorylation. Taken together, these data indicate that secreted Nucleobindin-2 is a suppressor of adipocyte differentiation through inhibition of cAMP production and insulin signal.
Export Options
About this article
Cite this article as:
Tagaya Yuko, Osaki Aya, Miura Atsuko, Okada Shuichi, Ohshima Kihachi, Hashimoto Koshi, Yamada Masanobu, Satoh Tetsurou, Shimizu Hiroyuki and Mori Masatomo, Secreted Nucleobindin-2 Inhibits 3T3-L1 Adipocyte Differentiation, Protein & Peptide Letters 2012; 19 (9) . https://dx.doi.org/10.2174/092986612802084546
DOI https://dx.doi.org/10.2174/092986612802084546 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Clinical Uses of 1-alpha-hydroxycholecalciferol
Current Vascular Pharmacology Is There an Association between Periodontitis and Hypertension?
Current Cardiology Reviews The Polyhedric Abl Kinases and their Pharmacologic Inhibitors
Current Enzyme Inhibition Secretory Expression of Human Protein in the Yeast Pichia pastoris by Controlled Fermentor Culture
Recent Patents on Biotechnology Beta-Blockers use for Hypertension in the Elderly
Cardiovascular & Hematological Agents in Medicinal Chemistry Intravitreal Triamcinolone in Diabetic Retinopathy
Current Diabetes Reviews CD36 as a Therapeutic Target for Endothelial Dysfunction in Stroke
Current Pharmaceutical Design Effects of Statins on Transplant Graft Arterial Diseases
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Obesity and its Association with Irisin Level Among Individuals with FNDC5/Irisin Gene Variants RS16835198 and RS726344
Protein & Peptide Letters Therapeutic Approach on AGE-RAGE Interaction and Its Function in Diabetic Inflammation Process
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) The Regulatory Roles of Mitogen-Activated Protein Kinase (MAPK) Pathways in Health and Diabetes: Lessons Learned from the Pancreatic β-Cell
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Glomerular Endothelium and its Impact on Glomerular Filtration Barrier in Diabetes: Are the Gaps Still Illusive?
Current Medicinal Chemistry Heightened Attention for Wnt Signaling in Diabetes Mellitus
Current Neurovascular Research Editorial (Thematic Issue: Modern Therapeutic Antibody Drug Discovery Technologies)
Current Drug Discovery Technologies miRNAs in Insulin Resistance and Diabetes-Associated Pancreatic Cancer: The ‘Minute and Miracle’ Molecule Moving as a Monitor in the ‘Genomic Galaxy’
Current Drug Targets Elevated Plasma Levels of Soluble TNFRs and TACE Activity in Alzheimer's Disease Patients of Northern Han Chinese Descent
Current Alzheimer Research Atherogenic Index of Plasma in Women with Rheumatoid Arthritis and Systemic Lupus Erythematosus: A 10-Year Potential Predictor of Cardiovascular Disease
Current Rheumatology Reviews Can We Move Forward After ADVANCE?
Vascular Disease Prevention (Discontinued) Postoperative Atrial Fibrillation - What Do We Really Know?
Current Vascular Pharmacology Intra-Renal Hemodynamic Changes After Habitual Physical Activity in Patients with Chronic Kidney Disease
Current Pharmaceutical Design